ArticleBlood cell therapy2021
Efficacy and safety of venetoclax in combination therapy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Article in Blood cell therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
- Analysis of interactions between posaconazole/voriconazole and venetoclax.Antimicrobial agents and chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy of the B-cell lymphoma 2 (BCL2)-inhibitor venetoclax in combination therapy for relapsed acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: We retrospectively analyzed 7 adults with relapsed AML who failed at least one prior therapy and were treated with venetoclax in combination with decitabine and/or low-dose cytarabine at the Beijing Boren hospital between March 2019 and March 2020. Four patients (57.1%) had adverse cytogenetic findings. Four patients (57.1%) had undergone a donor lymphocyte infusion (DLI) prior to venetoclax therapy, while four patients (57.1%) had leukemia and failed prior hypomethylating agent (HMA) therapy. Results: The objective response rate (ORR) was 71.4% (5 patients achieved morphological complete remission with incomplete hematologic recovery, CRi). At the end of the follow-up period, 3/5 cases (60%) in the CRi group achieved minimal residual disease (MRD) negativity by flow cytometry. One patient (14.3%) successfully underwent allo-HSCT. The median follow-up time was 140 (120, 354) d. Among the seven patients, one died of relapse after remission, with an overall survival rate of 85.7% and a disease-free survival rate of 57.1% (4/7). Five of these patients (71.4%) had an identifiable infection, including septicemia (one patient), herpes zoster (two patients), and pneumonia (two patients). One patient had a tumor lysis syndrome. Conclusion: The venetoclax-based combinations demonstrated efficacy in treating adult patients with AML relapsing after allo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.